Viking Therapeutics, Inc. (NASDAQ:VKTX) COO Marianna Mancini Sells 12,500 Shares

Posted by Defense World Staff on Apr 19th, 2023

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) COO Marianna Mancini sold 12,500 shares of the company’s stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $20.00, for a total value of $250,000.00. Following the transaction, the chief operating officer now directly owns 287,763 shares of the company’s stock, valued at $5,755,260. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Marianna Mancini also recently made the following trade(s):

On Wednesday, March 29th, Marianna Mancini sold 41,242 shares of Viking Therapeutics stock. The stock was sold at an average price of $16.00, for a total value of $659,872.00.

Viking Therapeutics Stock Up 3.8 %

VKTX opened at $20.38 on Wednesday. The business has a 50 day moving average price of $12.93 and a two-hundred day moving average price of $8.29. The company has a market cap of $1.60 billion, a PE ratio of -22.40 and a beta of 0.77. Viking Therapeutics, Inc. has a 52 week low of $2.02 and a 52 week high of $20.79.

Viking Therapeutics (NASDAQ:VKTX – Get Rating) last posted its quarterly earnings data on Wednesday, February 8th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.03). As a group, sell-side analysts expect that Viking Therapeutics, Inc. will post -0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VKTX has been the subject of several research reports. StockNews.com initiated coverage on Viking Therapeutics in a report on Thursday, March 16th. They issued a “sell” rating for the company. Stifel Nicolaus boosted their target price on Viking Therapeutics from $22.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, March 28th. HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of Viking Therapeutics in a report on Thursday, February 9th. Oppenheimer boosted their target price on Viking Therapeutics from $20.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, March 28th. Finally, Roth Mkm boosted their target price on Viking Therapeutics from $15.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, March 29th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.89.

Hedge Funds Weigh In On Viking Therapeutics

A number of large investors have recently modified their holdings of the business. Financial Insights Inc. raised its stake in shares of Viking Therapeutics by 7.1% during the 1st quarter. Financial Insights Inc. now owns 15,000 shares of the biotechnology company’s stock worth $250,000 after buying an additional 1,000 shares in the last quarter. Summit Financial Wealth Advisors LLC raised its stake in shares of Viking Therapeutics by 4.5% during the 1st quarter. Summit Financial Wealth Advisors LLC now owns 33,990 shares of the biotechnology company’s stock worth $566,000 after buying an additional 1,466 shares in the last quarter. Chartwell Investment Partners LLC purchased a new position in shares of Viking Therapeutics during the 4th quarter worth approximately $826,000. Steward Partners Investment Advisory LLC raised its stake in shares of Viking Therapeutics by 2,000.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,500 shares of the biotechnology company’s stock worth $99,000 after buying an additional 10,000 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC raised its stake in shares of Viking Therapeutics by 72.8% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 135,144 shares of the biotechnology company’s stock worth $1,270,000 after buying an additional 56,924 shares in the last quarter. 34.71% of the stock is owned by hedge funds and other institutional investors.

Viking Therapeutics Company Profile

(Get Rating)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.